anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The impact of prenatal exposure to a mixture of heavy metals on birth weight in newborns has been a topic of ongoing interest. In this study, 258 mothers and infants from the New Hampshire Birth Cohort Study (NHBCS) were selected as the study subjects, and the concentrations of seven heavy metals in the placenta, including Aluminum (Al), Cobalt (Co), Chromium (Cr), Nickel (Ni), Plumbum (Pb), Selenium (Se) and Arsenic (As) were collected. And the birth weight of newborns, the relevant covariates of mothers and newborns were collected. Three analytical methods, Weighted Quantile Sum (WQS) regression, Quantile g-computation (QGC) and Bayesian kernel machine regression (BKMR) were employed. After adjusting for maternal gestational age, pre-pregnancy BMI, smoking status, education level, parity, gestational age and newborn gender, the combined three methods showed that the total effect of mixed exposure of seven heavy metals on birth weight was negative. Specifically, the WQS analysis revealed that Se had the greatest impact on birth weight, followed by Al. The QGC results showed that the heavy metal associated with the reduction of birth weight was mainly Se and Al in female and male infants, respectively. The BKMR analysis demonstrated a negative combined effect of the seven heavy metals on birth weight in both male and female infants, with Se having the highest posterior inclusion probabilities (PIPs) for female infants (0.45), and Al having the highest PIPs for male infants (0.64) after stratification by gender. In summary, mixed exposure to heavy metals during pregnancy was associated with a decrease in newborn birth weight. Furthermore, there are gender effects with Se and Al associated with decreased birth weight in female and male infants, respectively. These findings provide a theoretical basis for the development of public health policies aimed at preventing adverse pregnancy outcomes and improving the health of newborns.
Prenatal multivitamin-mineral supplement called PregVit-folic 5® contains 5 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
PROBLEM TO BE SOLVED: To obtain a melamine production-inhibiting agent containing a specific compound having a strong inhibiting effect on the melamine production of live pigment cells, and further to obtain a preparation for external use for skin, having a beautifully whitening effect by adding the agent to a base agent in a constant concentration or higher. SOLUTION: This melamine production-inhibiting agent contains 2- hydroxycyclopentadecanone of the formula. The compound of the formula can be synthesized, e.g. by the acyloin condensation reaction of n- pentadecanedicarboxylic acid dimethyl ester as a raw material. The preparation for external use for skin contains the melamine production-inhibiting agent comprising the 2-hydroquinone cyclopentadecanone of the formula preferably in an amount of 0.0001-10wt.%, especially preferably 0.1-5wt.%. Especially, the preparation used for the preventing and improving the exacerbation of spots, freckles and dark skin contains the compound of the formula in an amount of >=0.1wt.%.
The method for assessing the cytotoxicity of the death-cup poison comprises the incubation of the death-cup extract with the suspension of the viable cells. Three specimens are studied: two with the samples of the poison and the control one. The equal volumes of suspension are placed onto three glass slides. The equal volumes of the poison are added to the test samples. The equal volume of 1% aqueous solution of Thiotriasolin as the antioxidant is added to one of the test samples. Then fluorochrom acridine orange is used to all samples. The samples are overlaid by the cover-slips and observed with the luminescent microscope upon 3-4-hours incubation at a temperature of 18-22 DEGREE c.
This is a nonrandomized (individuals will not be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), long-term safety follow-up study of abiraterone acetate in approximately 300 patients from other completed abiraterone acetate clinical studies. Patients must have received at least 3 months of treatment with abiraterone acetate and a low-dose corticosteroid and, based on investigator assessment, may benefit from continued treatment. This study will consist of a screening period followed by open-label treatment of continued abiraterone acetate access. The patients will continue with the same abiraterone acetate and low-dose corticosteroid dosing regimen they were receiving in the previous abiraterone acetate clinical study until the investigator determines that the patient is no longer receiving benefit or the sponsor terminates the study. Patients can be withdrawn from the study if an alternative access (eg, patient-assistance program or commercial source of abiraterone acetate) is available and feasible. Each cycle of treatment will be 28 days. Investigators will monitor and assess the patients for response to treatment or progression according to routine practice or as clinically indicated to determine whether continued treatment with abiraterone acetate is warranted. No efficacy data are being collected. Safety will be monitored throughout the study for a maximum duration of 9 years. End-of-study assessments will be performed at least 30 days after the last dose of abiraterone or upon early withdrawal.
The invention discloses a pharmaceutical composite for malignancy treatment and an application thereof. The pharmaceutical composite is proportionally prepared by curcumin and tetrandrine. The medicine prepared thereby comprises a preparation-allowed pharmaceutical excipient or carrier. The important point is that the synergistic effect of curcumin and tetrandrine on malignancy treatment is discovered. In particular, the pharmaceutical composite is applicable to glioma, lung cancer, liver cancer, gastric cancer, intestinal cancer, breast cancer, cervical cancer, pancreatic cancer and leukemia. The medicine has reasonable formulation, definite effective ingredients and obvious antitumor effect, and can reduce the clinical administration of the existing anticancer drugs, improve anticancer effect, reduce toxic side effect, and has application prospect of preparing antitumor drugs.
PURPOSE:To provide high efficiency in fractionation of blood plasma proteins by freezing and thawing a blood plasma protein-containing substance, subjecting the resultant substance to treatment with ethanol, anion exchanger, affinity chromatography, etc. CONSTITUTION:A blood plasma protein-containing substance is frozen, then thawed, filtered, etc., to provide a filtrate, etc., which are subsequently treated with ethanol in 5-10% concentration to recover fibrinogen, etc., from a precipitated fraction. The obtained supernatant is further treated with an anion exchanger to recover protopine, etc., from an adsorbed fraction. Unadsorbed fractions are then treated with affinity column chromatography using immobilized lysine to recover plasminogen from an adsorbed fraction. Unadsorbed fractions are further treated by the aforementioned chromatography with immobilized heparin to recover antithrombin-III from an adsorbed fraction. Unadsorbed fractions are subsequently treated with ethanol in 18-30% concentration to recover immunoglobulin, etc., from a precipitated fraction. The resultant supernatant is further treated with ethanol in 45% concentration to recover haptoglobin, etc., from a precipitated fraction and albumin from the supernatant. Thereby, the objective fractionation is carried out.
The Ketogenic Diet group will consume a very-low carbohydrate diet (\<50 g/day) diet. Participants will receive isocaloric packed-out meals for 26 weeks.
Implantation of the Carticel product should be restricted to physicians who have completed Vericel's Surgeon Training Program.

Implantation of the Carticel® product is performed during arthrotomy and requires both preparation of the defect bed and a periosteal flap to secure the implant. Complete hemostasis must be achieved prior to periosteal fixation and cell implantation. See the Carticel Surgical Manual, Vericel document #65021 for instructions on the performance of these procedures.

2.3.1 Implantation

  1. Insert the catheter tip through the superior opening of the periosteal chamber at the site of the defect. Advance catheter to most inferior aspect of the defect.
  2. Slowly inject a cell dose while moving the catheter tip from side to side and withdrawing the catheter proximally. This will ensure an even distribution of the cells throughout the defect.
  3. Complete the implantation by closing the superior opening of the periosteum as instructed. See Carticel Surgical Manual, Vericel document #65021.
MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression by inhibiting the translation of their specific target messenger RNAs. To date, numerous studies have demonstrated changes in the expression of miRNAs in the kidneys throughout the progression of both acute kidney injury (AKI) and chronic kidney disease (CKD) in both human patients and experimental models. The role of specific microRNAs in the pathogenesis of kidney diseases has also been demonstrated. Further studies have elucidated the regulation of these microRNAs in diseased kidneys. Besides, certain miRNAs are detected in plasma and/or urine in kidney diseases and are potential diagnostic biomarkers. In this review, we provide an overview of recent developments in our understanding of how miRNAs contribute to kidney diseases. We also explore the potential of miRNAs as both biomarkers and therapeutic targets for these conditions, and highlight future research directions.
Provided is a cosmetic gel sheet suitable for application in the fields of cosmetics and medicine. This cosmetic gel sheet has, as essential constituent components thereof, a carboxy group-containing water-soluble polymer, a polyvalent alcohol, and acid. A carboxy group-containing polysaccharide can be suitably used as the carboxy group-containing water-soluble polymer. The water content of the gel sheet is 30 wt% but ideally the water content is no more than 10 wt%. This cosmetic gel sheet can be produced by drying an aqueous solution including, as essential components thereof, a carboxy group-containing water-soluble polymer, a polyvalent alcohol, and acid. Ideally, the acid content in the aqueous solution is a suitable amount whereby the pH of the aqueous solution becomes 2.0-4.0.
Identifying compounds useful for modulating body weight, comprises contacting a test compound with a mammalian sequence 115. Identifying compounds useful for modulating body weight, comprises: (a) contacting a test compound with a mammalian sequence (b) 115; (c) determining whether the test compound binds to the mammalian sequence (d) 115; and (e) identifying a compound that binds to the mammalian sequence (f) 115 as a compound useful for modulating body weight. Independent claims are also included for: (1) a pharmaceutical formulation or composition, for modulating body weight, comprising a compound that modulates the activity of a mammalian sequence (2) 115, mixed with a pharmaceutical carrier; (3) a package comprising the pharmaceutical formulation of (1) and instructions for administering the pharmaceutical formulation for modulating body weight; (4) preparing a pharmaceutical composition useful for modulating body weight; (5) treating obesity and cachexia; and (6) an antibody that recognizes an isolated polypeptide comprising a sequence of 1014 or 337 amino acids (SEQ ID NOS: 5 or 6). ACTIVITY : Anorectic; Immunomodulator. No biological data given. MECHANISM OF ACTION : Gene Therapy.
506,451. Disinfectants ; sodium peroxide ; cleansing - compositions. PARIZOT, G. April 1, 1938, No. 10040. Convention date, April 5, 1937. [Class 81 (i)] [Also in Group III] Tablets comprising about 2 parts sodium peroxide and 3 parts sodium chloride are formed by compressing a mixture of these compounds. A substance, such as sodium phosphate, for precipitating hardening agents from hard water may be added to the mixture. Other agents, such as sodium carbonate or calcined soda, which do not decompose sodium peroxide,. may also be present. The tablets are used for the cleansing and disinfection of artificial dentures by placing them in water in which a denture is immersed. Specification 453,975 is referred to.
PROBLEM TO BE SOLVED: To obtain a detergent composition, capable of manifesting high detergency for foulings with a makeup cosmetic or sebum and having low irritation to skin by including a nonionic surfactant and a water-swellable clay mineral therein. SOLUTION: This detergent composition comprises (A) a nonionic surfactant (preferably a higher fatty acid ester of polyethylene glycol, etc.) and (B) a water-swellable clay mineral (preferably smectite). The composition preferably comprises 1-40wt.% ingredient A and 1-10wt.% ingredient B therein. A mono- or a dihydric or a polyhydric alcohol, an inorganic powder and a water-soluble polymer can preferably further be contained therein. Thereby, the composition can be utilized as a gel, a cream, etc., which are stable, readily taken onto a hand or a face and excellent in massaging and rinsing properties.
Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (att), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded.
PROBLEM TO BE SOLVED: To obtain both a wound treating substance showing excellent treating effect on wound and a wound treating agent containing the substance. SOLUTION: This wound treating substance comprises a new peptide of the formula. The wound treating substance is obtained by culturing a strain belonging to the genus Streptomyces, capable of producing the wound treating substance, such as Streptomyces karnatakensis (JCM4485) of an actinomyces by liquid culture under an aerobic condition, extracting the prepared culture solution, its dried substance by evaporation or its culture cell with an organic solvent (e.g. ethyl acetate), subjecting the extracted substance to column chromatography and recrystallizing the resultant substance. The peptide of the formula in an amount of 10<-10> to 50wt.% is used as an active ingredient and pharmaceutically manufactured into an oral administration form, injection, suppository, plaster, ointment, cream, inhalant, nasal drop, spray agent, etc.  A dose is usually 1mg to 10 mg/kg calculated as the peptide per day.
The intervention to be carried out in the treatment group is the use of the therapy measures for the treatment of arterial hypertension, which is delivered through the iATROS medical device. The therapy by means of the medical device takes place over 90 days.
Venous thromboembolism is one of the leading causes of maternal morbidity and mortality, and antepartum hospitalizations place pregnant patients at an even higher risk of developing thromboembolism. As a result, there is an increased emphasis on administering pharmacologic thromboprophylaxis for antepartum patients with prolonged hospitalizations. Previously, standard dosing of unfractionated heparin was widely adopted for thromboprophylaxis in the pregnant population. However, due to a suspected altered metabolism of unfractionated heparin in pregnancy resulting in a decrease response, the American College of Obstetricians and Gynecologists (ACOG) currently recommends considering gestational age-based dosing for unfractionated heparin for thromboprophylaxis in pregnancy with standard dosing as an alternative option. The data supporting altered dosing is very limited. In addition, increased dosing of heparin may result in challenges in anesthetic management, potentially limiting the receipt of neuraxial anesthesia resulting in increased need for general anesthesia associated with both increased maternal and fetal risks. The potential effects of higher prophylactic unfractionated heparin dosing in pregnant patients need to be further explored before being widely adopted for inpatient antepartum thromboprophylaxis. The investigators propose this study to provide a direct comparison of gestational age-based unfractionated heparin dosing to standard dosing of unfractionated heparin for pharmacologic thromboprophylaxis of hospitalized antepartum patients.
The technique of single maximal inhalation will be demonstrated to all the patients by a technician. In brief the patient will be asked to inhale slowly and maximally and hold the breath for at least 5 seconds. After the breath holding maneuver the patient will be asked to exhale. Salbutamol (100µg) be administered in a dose of 2 puffs, each after a one minute interval. The duration of the breath hold will be measured by a stop watch.
Up to 20 patients diagnosed with type 2 diabetes mellitus and hyperglycemia will be enrolled and assigned to a single treatment group. Patients will give a small amount of peripheral blood and the blood will be processed and cultured in our laboratory. The ex vivo activated autologous blood cells will be infused intravenously back to patients. The treatment will be done twice a week for consecutive 4 weeks. The metabolic parameters of patients before and after the therapy will be compared to determine if the therapy is safe and effective.
Each participant will be enrolled for 14 weeks (4 weeks baseline, 8 weeks of drug exposure, and 2 weeks follow-up). After clinical assessment by the investigator if deemed safe and appropriate, and requested by the caregiver, participants may continue to receive the study medication ("extended use"), up to December 2025. Participants who remain on phenylbutyrate therapy will be followed quarterly through video visits, and yearly in-person visit. Participants who do not opt to remain on phenylbutyrate therapy will be weaned off the medication during the 2 week follow-up period.
Group A participants will be prescribed oral senna (Senokot; Atlantis Consumer Healthcare Inc., Bridgewater, NJ) 8.6mg tablets and be instructed to start with two tablets on the morning of Post Operative Day (POD)#1. Participant will continue taking two tablets on the daily. If no bowel movement on the morning of POD#3 participant may take 2 tablets in the morning and another 2 tablets that evening. The same can be replicated on POD#4. If no bowel movement on the morning of POD#5 participant may take magnesium hydroxide (Phillips' Milk of Magnesia; Bayer AG, Leverkusen, Germany) 30 mL by mouth and need to call the urology clinic for further instruction.
Individuals considered resilient can overcome adversity, achieving normal physical and psychological development, while those deemed vulnerable may not. Adversity promotes structural and functional alterations in the medial prefrontal cortex (mPFC) and hippocampus. Moreover, activity-dependent synaptic plasticity is intricately linked to neuronal shaping resulting from experiences. We hypothesize that this plasticity plays a crucial role in resilience processes. However, there is a notable absence of studies investigating this plasticity and behavioral changes following social adversity at different life stages. Consequently, we evaluated the impact of social adversity during early postnatal development (maternal separation [MS]), adulthood (social defeat [SD]), and a combined exposure (MS + SD) on behavioral outcomes (anxiety, motivation, anhedonia, and social interaction). We also examined cFos expression induced by social interaction in mPFC and hippocampus of adult male rats. Behavioral analyses revealed that SD-induced anhedonia, whereas MS + SD increased social interaction and mitigated SD-induced anhedonia. cFos evaluation showed that social interaction heightened plasticity in the prelimbic (PrL) and infralimbic (IL) cortices, dentate gyrus (DG), CA3, and CA1. Social interaction-associated plasticity was compromised in IL and PrL cortices of the MS and SD groups. Interestingly, social interaction-induced plasticity was restored in the MS + SD group. Furthermore, plasticity was impaired in DG by all social stressors, and in CA3 was impaired by SD. Our findings suggest in male rats (i) two adverse social experiences during development foster resilience; (ii) activity-dependent plasticity in the mPFC is a foundation for resilience to social adversity; (iii) plasticity in DG is highly susceptible to social adversity.
* Use during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning [see Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)].
  * Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Myfortic. Patients receiving Myfortic should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions (5.2)].
  * Increased risk of development of lymphoma and other malignancies, particularly of the skin, due to immunosuppression [see Warnings and Precautions (5.3)].
  * Increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections [see Warnings and Precautions (5.4, 5.5)].
If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
PURPOSE:To obtain a skin drug for external use, by blending an extract of Centella asiatica Urb. with vitamins A, E, D and/or C and having improved effects on improvement of skin roughening and keratin, promotion of turnover rate and wound curing as well as prevention of skin aging. CONSTITUTION:A skin drug for external use, obtained by blending (A) an extract of Centella asiatica Urb. with (B) one or more vitamins selected from vitamins A, E, D and C and having the above-mentioned effects. The amount of the ingredients are 0.0001-5.0wt% (dried solid content) ingredient (A) and 0.0001-5.0wt% ingredient (B). The above-mentioned extract is obtained by refluxing leaves of the Centella asiatica Urb. with a solvent, e.g. lower alcohol such as methanol, ethanol, etc., hydrous lower alcohol, 1,3-butylene glycol, propylene glycol or hydrous polyhydric alcohol, etc., while heating, filtering the resultant extract and concentrating the resultant filtered extract.